8-K: Rhythm Pharmaceuticals' Setmelanotide Achieves Primary Endpoint in Phase 3 TRANSCEND Trial for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announces positive topline results from its Phase 3 TRANSCEND trial, demonstrating a statistically significant and clinically meaningful reduction in BMI with setmelanotide in patients with acquired hypothalamic obesity.

Summary

• Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND clinical trial evaluating setmelanotide for acquired hypothalamic obesity.
• The trial met its primary endpoint, showing a statistically significant and clinically meaningful reduction in body mass index (BMI) in both adult and pediatric patients compared to placebo.
• Patients on setmelanotide experienced a mean BMI reduction of -16.5% from baseline, compared to a +3.3% BMI change for patients on placebo at 52 weeks (p<0.0001).
• The placebo-adjusted difference in BMI reduction was -19.8% (N=120).
• For adult patients (18 years and older), the placebo-adjusted BMI reduction was -19.2%, while for patients younger than 18 years, it was -20.2%.
• 80% of patients on setmelanotide achieved a BMI reduction of 5% or greater at 52 weeks.
• Clinically meaningful improvements were observed across key secondary endpoints, including a reduction in hunger scores.
• Setmelanotide was generally well-tolerated, with no new safety signals observed.
• The most common treatment-emergent adverse events were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, and headache.
• The company expects existing cash and cash equivalents and short-term investments to be sufficient to fund planned operations into 2027.
• Regulatory submissions in the U.S. and EU are anticipated to be completed in the third quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents positive topline results from a Phase 3 trial, indicating a significant clinical benefit for setmelanotide in treating acquired hypothalamic obesity. The safety profile appears acceptable, and the company anticipates regulatory submissions. The overall tone is optimistic and suggests a positive outlook for the company.

Positives

• The Phase 3 TRANSCEND trial met its primary endpoint with statistically significant BMI reduction.
• Setmelanotide was generally well-tolerated with no new safety signals.
• Clinically meaningful improvements were observed across key secondary endpoints, including hunger scores.
• Regulatory submissions are planned for Q3 2025.
• Existing cash is expected to fund operations into 2027.

Negatives

• The most common treatment-emergent adverse events were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, and headache.
• One drug-related serious adverse event was reported, although no serious adverse events led to study discontinuation.
• One death occurred during the trial, but it was deemed not related to the study drug.

Risks

• The success of regulatory submissions is not guaranteed.
• The commercial success of setmelanotide depends on market acceptance and reimbursement.
• The company faces competition in the obesity treatment market.
• The company's forward-looking statements are subject to numerous risks and uncertainties, including clinical trial outcomes and regulatory approvals.

Future Outlook

Rhythm Pharmaceuticals is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025. The company anticipates presenting full data from the TRANSCEND study at an upcoming medical meeting. The company expects existing cash to fund operations into 2027.

Management Comments

• David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm, stated that the results from the TRANSCEND study potentially represent a transformational milestone for Rhythm.
• David Meeker, M.D. stated that the company is preparing to submit regulatory applications based on the compelling efficacy data.
• Susan Phillips, MD, pediatric endocrinologist at Rady Childrens Hospital-San Diego and professor of pediatrics at UC San Diego School of Medicine, stated that the data are highly clinically meaningful, offering hope that a new targeted therapy may become available for patients living with acquired hypothalamic obesity.

Industry Context

The announcement addresses a significant unmet need in the treatment of acquired hypothalamic obesity, a rare and serious disease with limited treatment options. The positive results from the TRANSCEND trial position setmelanotide as a potential first-ever approved therapy for this patient population. This could give Rhythm a significant advantage in the market for rare neuroendocrine diseases.

Comparison to Industry Standards

• The TRANSCEND trial is described as the largest and longest placebo-controlled trial to evaluate a therapy for patients with acquired hypothalamic obesity, suggesting a higher standard of evidence compared to previous studies.
• Current approaches, including lifestyle interventions and pharmacotherapy intended for general obesity, have shown limited effectiveness in achieving long-term, durable weight loss, highlighting the potential advantage of setmelanotide as a targeted therapy.
• Other companies developing obesity treatments include Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Mounjaro), but these are generally targeted at broader obesity indications rather than the specific condition of acquired hypothalamic obesity.

Stakeholder Impact

• Shareholders: Positive results could lead to increased stock value.
• Patients: Offers a potential new treatment option for a rare and serious condition.
• Employees: Positive results could improve morale and job security.

Next Steps

• Rhythm Pharmaceuticals plans to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.
• The company anticipates presenting full data from the TRANSCEND study at an upcoming medical meeting.
• The company will continue to advance its clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718.
• Topline data from 12-patient Japanese cohort in acquired HO anticipated in Q1 2026.
• Phase 2 trial in Prader-Willi syndrome enrollment completion anticipated in Q3 2025.
• Topline data from Ph3 EMANATE trial in MC4R pathway diseases anticipated in Q1 2026.
• First patient to be dosed in Ph3 congenital HO substudy anticipated in Q2 2025.

Key Dates

Keywords

setmelanotide, hypothalamic obesity, TRANSCEND trial, Rhythm Pharmaceuticals, BMI reduction, clinical trial, regulatory submission, MC4R agonist, obesity, IMCIVREE